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Summary
Background Vitiligo is a pigmentary disorder which may have disfiguring conse-
quences. Its treatment remains a challenge.
Objectives We designed a parallel-group randomized controlled trial to compare
the effectiveness of 308-nm excimer laser alone or in combination with topical
hydrocortisone 17-butyrate cream in patients with vitiligo unresponsive to previ-
ous treatment with topical steroids or narrow-band ultraviolet (UV) B photo-
therapy.
Methods Consecutive patients aged 18–75 years with nonsegmental vitiligo local-
ized on the face and ⁄or neck lacking response to previous conventional treatment
were eligible. In total, 84 patients (44 women and 40 men, mean age 44 years)
were randomized to 308-nm excimer laser phototherapy twice weekly alone or
in combination with topical hydrocortisone 17-butyrate cream twice daily for
three periods of 3 weeks followed by a 1-week steroid-free interval. The primary
outcome was a reduction of at least 75% of the overall lesional areas as judged
by automatic image analysis on reflected UV photographs, conducted blind to
treatment assignment, at 12 weeks compared with baseline. Secondary outcomes
were clearance, and improvements on Physician’s Global Assessment (PGA) and
Skindex-29 scores.
Results A total of 76 (90%) patients completed the study. In an intention-to-treat
analysis, seven [16Æ6%; 95% confidence interval (CI) 5Æ3–27Æ8%] patients in the
excimer monotherapy arm and 18 (42Æ8%; 95% CI 27Æ8–57Æ8%) in the combin-
ation arm showed ‡ 75% reduction of vitiligo lesions at 12 weeks (v2 test 6Æ89,
P = 0Æ0087). Clearance was observed in two (4Æ7%; 95% CI 1Æ6–11Æ2%) and
nine (21Æ4%; 95% CI 9Æ0–33Æ8%) patients, respectively (Fisher’s exact test
P = 0Æ04). A significant difference also emerged for PGA scores, while no differ-
ence was documented for Skindex-29.
Conclusions Recalcitrant vitiligo of the face and neck may benefit from the combin-
ation of excimer laser phototherapy with topical hydrocortisone 17-butyrate
cream.
Vitiligo is an acquired cutaneous disorder characterized by
well-circumscribed depigmented macules due to the dis-
appearance of functional melanocytes in the lesional areas,
affecting 0Æ1–1% of the general population.1–4 In the vast
majority of patients, depigmentation is accompanied by influx
to the skin of T lymphocytes reactive with melanocyte-specific
antigens and secreting type 1 proinflammatory cytokines.5 All
body surface areas can be affected, the most common ones
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being the face, the dorsum of the hands, the axillae, the
umbilicus, the sacrum and the inguinal region. According to
the distribution of depigmented lesions, focal, generalized
(usually symmetrical) or universal varieties are distinguished.
Segmental vitiligo is characterized by unilateral lesions with
dermatomal distribution and is considered as a separate entity.
The natural course of vitiligo is highly variable but is usually
slowly progressive in a stepwise manner. Spontaneous
repigmentation is not uncommon but is rarely complete.
Vitiligo patches are asymptomatic but may be disfiguring
especially in dark-skinned populations.6 A systematic review
published in 2006 pointed out that the methods currently
available to treat vitiligo are largely unsatisfactory and vary
widely between cultures and within health systems.7 An
earlier meta-analysis which included large case series besides
randomized trials concluded that class III topical steroids and
ultraviolet (UV) B phototherapy were the most effective and
safest therapies for localized and generalized vitiligo, respec-
tively.8 No data are available about the combination of UVB
phototherapy and topical steroids.
The introduction of xenon chloride excimer laser generating
monochromatic light at 308 nm allows for targeted photo-
therapy and selective treatment of localized lesions.9,10 We
hypothesized that 308-nm excimer laser phototherapy and
topical steroids could have a synergistic effect in treating recal-
citrant vitiligo lesions. We designed a parallel-group random-
ized controlled trial (RCT) to compare the effectiveness of
308-nm excimer laser alone or in combination with topical
hydrocortisone 17-butyrate cream in patients with vitiligo
unresponsive to previous treatment with topical steroids or
narrow-band UVB (NB-UVB) phototherapy.
Materials and methods
Patients
Patients were recruited between November 2005 and June 2007
from the Department of Dermatology of the General Hospital of
Bergamo and from the Department of Dermatology of the Uni-
versity of Verona, in Italy. Eligible patients aged 18–75 years
had focal or generalized vitiligo, were looking for treatment of
vitiligo lesions of the face and ⁄or neck, had a history of insuffi-
cient response to previous NB-UVB phototherapy or topical
steroids (a minimum 16-week NB-UVB treatment course at a
recognized phototherapy centre, or a 12-week intermittent or
continuous treatment with potent topical steroids under medical
supervision), and had not been previously treated by 308-nm
excimer laser. Patients with purely segmental vitiligo, character-
ized by unilateral lesions with dermatomal or quasidermatomal
distribution, were excluded.
Patients were excluded if they were pregnant or breast-feed-
ing, and if they had a history of diseases associated with
excessive reaction to visible or UV radiation (e.g. porphyria
cutanea tarda, polymorphic light eruption) or reported photo-
sensitivity. The study was approved by the medical ethics
committee at each centre.
Design
Eligible patients who had given written informed consent
were randomly assigned on a 1 : 1 basis to receive 12 weeks
of treatment with either 308-nm excimer laser or excimer
laser plus topical hydrocortisone 17-butyrate cream. Stratified,
blocked randomization was used to balance age and gender.
Centralized telephone randomization procedures were adopted
and investigators were blinded to the randomization rule. The
screening period, during which no active treatment for vitiligo
was permitted, lasted 4 weeks in subjects on topical steroids
and 8 weeks in subjects on phototherapy or photochemo-
therapy. After 12 weeks of treatment, the patients were moni-
tored for another 4 weeks.
Treatment regimens
The laser used was a xenon chloride excimer laser generating
monochromatic light at 308 nm, with pulse frequency of
200 Hz, pulse duration of about 30 ns, energy density
(fluence) of 3 mJ cm)2 and spot size of 4Æ0 cm2 (XTRAC exci-
mer laser; PhotoMedex, Montgomeryville, PA, U.S.A.). All the
lesions in the affected areas were treated at each treatment
session. Lesions were treated twice weekly for 12 weeks. Initial
fluences in the vitiligo areas were half the minimal erythema
dose (MED) determined on normal nonsun-exposed skin.
Fluences were increased by half the MED at every other session.
If intense local reactions with vesicles or bullae developed, the
treatment was withheld and then resumed after resolution, at
the last dose without reaction. If an intense reaction followed
the first laser application then the initial dose was further
reduced by one half after the resolution of the reaction. Patients
randomized to the combination treatment arm received 308-
nm excimer laser treatment as indicated above plus topical
hydrocortisone 17-butyrate 0Æ1 g ⁄100 g hydrophilic cream
twice daily during three periods of 3 weeks, followed by a
1-week steroid-free interval. Patients were instructed to apply
one thin layer of the cream over all the vitiligo patches of the
face and neck. Topical steroids were applied twice daily, in
the morning and in the evening. The phototherapy sessions
were conducted at midday or during early afternoon. During
the study period no treatment or only camouflage was allowed
on body areas other than face and neck.
Outcomes
Effectiveness
Standardized photographs under visible and UV (Wood’s lamp)
illumination were taken at baseline and after 4, 8, 12 and
16 weeks of starting treatment. A Wood’s lamp delivers UV
radiation at a wavelength of approximately 365 nm and
through the technique of reflected UV photography it allows
vitiligo lesions to be traced unambiguously. The primary out-
come measure was a reduction of at least 75% of the overall
lesional areas as judged by image analysis on reflected UV
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photographs at 12 weeks compared with baseline. Image
analysis was based on software specifically developed using
MATLAB (MathWorks, Natick, MA, U.S.A.) and was con-
ducted by an investigator who was unaware of treatment
assignments. Clearance, i.e. disappearance of all the vitiligo
lesions in the treated areas, as judged by image analysis on
reflected UV photographs, at 12 weeks after starting treatment,
represented a secondary outcome measure. Physician’s Global
Assessment (PGA) was evaluated on an anchored horizontal 10-
cm visual analogue scale at baseline and at 8, 12 and 16 weeks
after starting treatment. Improvement at 12 weeks was assessed
as percentage over values at baseline as a secondary outcome
measure.
Quality of life
As a patient-reported outcome we used the Italian version
of Skindex-29, a validated, self-administered questionnaire,
including 30 items all of which are weighted equally to pro-
duce an overall composite score.11 Patients completed Skin-
dex-29 at baseline and at weeks 8, 12 and 16 thereafter.
Normalized Skindex scores ranged from 0 to 100, with higher
values indicating a higher impact on the quality of life.
Changes were expressed as differences between final and ini-
tial scores.
Side-effects
We evaluated side-effects known to be associated with photo-
therapy and topical steroid use, and any other unexpected
adverse event. In particular, we considered erythemal reactions
needing temporary or permanent treatment discontinuation
and steroid atrophic changes and hypertrichosis. These were
evaluated at each treatment session.
Statistical analysis
The proportion of treatment successes, i.e. improvement
‡ 75% on image analysis of reflected UV photographs, was
compared between groups by using the v2 test. An intention-
to-treat approach was adopted in the primary analyses. This
considered patients withdrawn prematurely from the study as
a treatment failure for the corresponding treatment arm.
Intention-to-treat analysis was further complemented by per-
protocol analyses, which considered only those patients who
completed the study period. Similar analyses but using Fisher’s
exact test were conducted when considering clearance as a
secondary outcome measure. Nonparametric analytical tests
(i.e. Mann–Whitney U-test) were used to compare mean dif-
ferences in vitiligo areas, PGA scores, and Skindex-29 scores.
When designing this trial, we calculated that 42 patients
would be needed in each group for the study to have a 95%
power to rule out a difference of 20% or more in the propor-
tion of responders between randomized groups at 12 weeks.
No interim analyses were performed. Two-sided P-values of
< 0Æ05 were considered to indicate statistical significance.
Results
Patients
Between November 2005 and June 2007, 102 patients were
screened, 84 of whom (44 women and 40 men, mean age
44 years) underwent randomization (Fig. 1). Reasons for not
including screened patients were vitiligo in areas other than
face and neck (n = 6), nonvitiligo lesions (n = 4), no previ-
ous treatment with topical steroids or NB-UVB (n = 3), inabil-
ity to comply with treatment schedule (n = 3), previous
treatment with excimer laser (n = 1) and pregnancy (n = 1).
The baseline characteristics of randomized patients are
shown in Table 1. Eight patients, six in the excimer laser
monotherapy group and two in the combined excimer laser
plus topical hydrocortisone 17-butyrate cream group, with-
drew after inclusion in the study.
Cumulative UV doses ranged from 3Æ0 to 18Æ1 J cm)2
(mean 8Æ8) in the monotherapy group and from 3Æ5 to
20Æ1 J cm)2 (mean 9Æ2) in the combination group (Mann–
Whitney U-test P = 0Æ573).
Effectiveness
The distribution of patients according to the degree of
repigmentation at 12 weeks is reported in Fig. 2. The mean
repigmentation percentage was 20Æ5% in the excimer laser
monotherapy group and 40Æ0% in the excimer laser plus
topical steroid combination group (Mann–Whitney U-test
Assessed for eligibility
(n = 102)
Excluded  (n = 18) 
Not meeting inclusion criteria
(n = 16)
Refused to participate
(n = 2)
Analysed (n = 36)
Discontinued intervention 
(n = 6)
Withdrew consent (n = 3) 
Side-effects (n = 2) 
Noncompliance (n = 1) 
Allocated to laser monotherapy
(n = 42)
Received allocated intervention
(n = 42)
Discontinued intervention 
(n = 2)
Withdrew consent (n = 2)
Allocated to combined laser plus 
topical steroid 
(n = 42) 
Received allocated intervention
(n = 42)
Analysed (n = 40)
Randomized (n = 84)
Fig 1. Consort diagram of patient disposition.
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P = 0Æ02). A total of 25 patients reached the threshold for a
satisfactory response as indicated by our primary endpoint,
i.e. a reduction of ‡ 75% in the treated vitiligo areas com-
pared with baseline, at 12 weeks (Table 2). There were seven
patients [16Æ6%; 95% confidence interval (CI) 5Æ3–27Æ8%] in
the monotherapy group and 18 (42Æ8%; 95% CI 27Æ8–57Æ8%)
in the combined treatment group (v2 test 6Æ89, P = 0Æ0087
on intention-to-treat analysis). Clearance was observed in two
(4Æ7%; 95% CI 1Æ6–11Æ2%) and nine (21Æ4%; 95% CI 9Æ0–
33Æ8%) patients, respectively (Fisher’s exact test P = 0Æ04).
A significant difference between treatment groups was also
documented for variations in PGA at 12 weeks. The mean
PGA improvement was 29Æ7% (SEM 4Æ4) in the laser mono-
therapy group and 51Æ2% (SEM 5Æ1) in the combination group
(Mann–Whitney U-test P = 0Æ004). No documentation of an
impact of associated autoimmune disease or clinical variety of
vitiligo (i.e. focal vs. generalized lesions) was obtained in sub-
group analyses. However, this result should be taken with
caution due to limited sample size and post-hoc analyses (data
not presented).
Table 1 Baseline characteristics of randomized
patients Excimer laser
monotherapy
(n = 42)
Combination
therapy
(n = 42) P-value
Gender
Male 20 20
Female 22 22 1
Age (years), mean ± SEM 44Æ1 ± 2Æ1 42Æ4 ± 1Æ8 0Æ632
Weight (kg), mean ± SEM 68Æ32 ± 1Æ93 69Æ21 ± 1Æ89 0Æ615
Height (cm), mean ± SEM 170Æ44 ± 1Æ08 171Æ14 ± 1Æ19 0Æ746
Smoking habits
Smokers 15 11
Nonsmokers ⁄previous smokers 27 31 0Æ345
Alcohol consumption
Regular drinkers 8 6
Occasional ⁄nondrinkers 34 36 0Æ558
Skin phototype (Fitzpatrick classification)
I–II 24 26
III–IV 18 16 0Æ656
Eye colour
Blue-green 11 14
Brown 31 28 0Æ474
Hair colour
Blond ⁄ red ⁄ light brown 12 11
Dark brown ⁄black 30 31 0Æ806
Family history of vitiligo (first-degree relatives)
Yes 19 16
No 23 26 0Æ506
Personal history of autoimmune diseasesa
Yes 9 7
No 33 35 0Æ578
Vitiligo variety
Focal 10 9
Generalized 32 33 0Æ80
Percentage of area involved at starting treatment (face and neck)
< 3% 17 15
3–15% 20 19 0Æ656
> 15% 5 8
Disease duration (years), mean ± SEM 21Æ6 ± 1Æ7 18Æ6 ± 1Æ7 0Æ1679
No. previous different treatments for vitiligo
1 32 28
2+ 10 14 0Æ334
aThese included eight cases of autoimmune thyroid disease and one case of chronic
inflammatory bowel disease in the excimer laser monotherapy arm, and seven cases of
autoimmune thyroid disease in the combination therapy arm. For continuous variables,
values are expressed as means ± SEM, otherwise, as the number of patients in the speci-
fied category. P-values are calculated from Mann–Whitney U-test for continuous variables
and v2 test for categorical or discrete variables.
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Quality of life
Quality of life indices improved to a similar extent in the two
treatment groups. The values of the composite score at entry
were 19Æ4 (SEM 2Æ53) in the laser monotherapy group and
23Æ71 (SEM 2Æ18) in the combination group. At the end of
the treatment course, values decreased to 14Æ22 (SEM 2Æ25)
and 18Æ97 (SEM 2Æ3), respectively (Mann–Whitney U-test for
between-group comparison, P = 0Æ727).
No significant differences were found between groups for
any of the Skindex-29 subscales. Overall, variations were
)0Æ50 (SEM 1Æ72) for symptoms, )7Æ5 (SEM 1Æ21) for emo-
tion, and )2Æ08 (SEM 0Æ97) for social functioning subscales.
Side-effects
A total of 71 (84Æ5%) patients developed some degree of ery-
thema at some stage during their treatment. Moderate-
to-severe erythemal reactions requiring temporary withdrawal
of treatment occurred in a total of 50 (59Æ5%) patients, 28
(66Æ6%) in the monotherapy and 22 (52Æ3%) in the combin-
ation group. There was one patient with some degree of
hyperpigmentation in the monotherapy group and five in the
combination group. No clinically appreciable occurrence of
skin atrophy or hypertrichosis was reported. No other serious
or irreversible side-effects were observed.
Follow-up
All the 76 patients who completed a 12-week treatment per-
iod were followed up for an additional 4 weeks. At week 16
there were no substantial differences compared with observa-
tions at week 12.
Discussion
This RCT provides evidence that twice weekly phototherapy
delivered by a xenon chloride excimer laser generating mono-
chromatic light at 308 nm combined with cycles of topical
hydrocortisone 17-butyrate cream twice daily for 3 weeks
followed by a 1-week steroid-free interval provides better
repigmentation results than excimer laser phototherapy alone,
in patients with vitiligo of the face and neck and a history of
unsatisfactory response to NB-UVB or topical steroids.
Even though both UVB phototherapy and topical steroids
are established treatment for vitiligo, little is known about
their combined effect and no RCTs are available. Interestingly,
encouraging results were obtained a few years ago, in a
within-patient control study combining UVA with topical ste-
roids for the treatment of vitiligo lesions on the arms, legs
and trunk.12 We aimed to assess whether the use of topical
corticosteroids added to the efficacy of excimer laser and was
worth the risk of atrophogenic effects or hypertrichosis. Actu-
ally, by adopting our intermittent regimen no clinically evalu-
able steroid-related adverse effect was documented while it is
conceivable that steroid use, besides adding to efficacy, influ-
enced a reduced rate of UV-related erythematous reactions
in the combination arm compared with excimer laser mono-
therapy.
To date, NB-UVB therapy is one of the most established
treatments for extensive vitiligo lesions.7 The mechanism of
action of UVB-based treatment is not fully understood. Prolif-
eration and migration of melanocytes present in the hair folli-
cles certainly play a role. In addition, UV may exert an
immunosuppressive action with depletion of Langerhans cells
and apoptosis of activated T lymphocytes.13 In principle, exci-
mer laser presents several advantages compared with NB-UVB
therapy especially for treating vitiligo of limited extent. Photo-
biological effects are deemed to be stronger due to a greater
induction of lymphocyte apoptosis.14 Moreover, the laser
articulated arm can reach virtually any kind of localization and
selectively target vitiliginous lesions while sparing the healthy
skin.15–18 Differences in treatment response according to body
areas have been repeatedly documented in vitiligo, and UV-
sensitive and UV-resistant areas are identified.19 We restricted
our study to UV-sensitive areas, i.e. face and neck. This aspect
of the study obviously limits the generalization of our results
to other more challenging skin regions, e.g. dorsum of hands.
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Fig 2. Distribution of patients according to percentage of
repigmentation at 12 weeks.
Table 2 Number of patients achieving ‡ 75% repigmentation of
vitiligo lesions at 12 weeks (primary outcome of treatment)
Percentage of
repigmentation
Laser
monotherapy
Laser plus
topical steroid
combined treatment Total
Intention-to-treata
< 75% 35 24 59
‡ 75% 7 18 25
Per-protocolb
< 75% 29 22 51
‡ 75% 7 18 25
av2 test (d.f. = 1) 6Æ8908, P = 0Æ0087; bv2 test (d.f. = 1)
5Æ6058, P = 0Æ0179.
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Besides topical steroids, to increase response rates of
phototherapy, several combination modalities have been pro-
posed, including topical vitamin D derivatives and topical
calcineurin inhibitors. While for the combination of UVB
with topical steroids no RCTs were identified before we per-
formed our study, for the other combinations a few RCTs
are available.18,20–22 Unfortunately, these studies adopted a
within-patient study design where individual patches rather
than whole patients were evaluated. As a consequence, the
studies provide only hints about the overall therapeutic effect
of the strategies being assessed. Based on our results, paral-
lel-group RCTs of different phototherapy combination treat-
ments, including a steroid combination arm, are necessary to
identify the best management strategy. Our study was not
designed to document long-term effects and longer studies
are needed to confirm the efficacy and safety of the treat-
ment we have evaluated. As for other vitiligo therapies, an
increased duration of treatment may increase the percentage
of responders.19
Our clinical results were not paralleled by a difference in
quality of life scores as assessed by Skindex-29, because
similar improvements in quality of life indices were
observed at the end of the study in the two treatment
groups. Skindex-29 is a dermatology-specific quality of life
questionnaire but it may not be best suited to assess vitiligo
and its sensitivity to change may be limited.23 On the other
hand, that objective clinical improvements may not be par-
alleled by similar changes in quality of life indices is not
surprising and has been documented for other skin dis-
orders as well.24 Physicians treating skin disorders should
be aware that even in the presence of substantial clinical
improvement patients may still substantially suffer psycho-
logically.24
In conclusion, vitiligo of the face and neck unresponsive to
previous treatment with conventional phototherapy and ⁄or
topical steroids may benefit from the combination of 308-nm
excimer laser phototherapy with topical hydrocortisone
17-butyrate cream. The treatment is well tolerated. Clinical
effects do not necessarily translate into improvements in qual-
ity of life scores.
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